Treating Painful Diabetic Peripheral Neuropathy: An Update

Area of Science:

• Neurology
• Endocrinology
• Pharmacology

Background:

• Diabetic peripheral neuropathy (DPN) affects roughly 25% of diabetes mellitus patients.
• DPN significantly impairs patients' quality of life with symptoms like burning pain and numbness.
• Symptoms typically manifest in a stocking-glove distribution, progressing proximally from extremities.

Purpose of the Study:

• To review current treatment strategies for painful diabetic peripheral neuropathy.
• To outline first-line, second-line, and third-line therapeutic options based on practice guidelines.
• To discuss the role of various medications and interventions in managing DPN.

Main Methods:

• Review of current clinical practice guidelines for DPN management.
• Identification of FDA-approved medications for DPN.
• Categorization of treatments into first-line, second-line, and third-line therapies.
• Evaluation of evidence supporting complementary and alternative medicine approaches.

Main Results:

• Pregabalin and duloxetine are FDA-approved for DPN.
• First-line treatments include pregabalin, duloxetine, gabapentin, and amitriptyline.
• Second-line options include tramadol, tapentadol, venlafaxine, desvenlafaxine, lidocaine patches, and capsaicin cream.
• Isosorbide dinitrate spray and TENS may be considered at any point.
• Opioids and SSRIs are optional third-line treatments.
• Acupuncture, TCM, alpha lipoic acid, acetyl-l-carnitine, primrose oil, and EMF lack high-quality supporting evidence.

Conclusions:

• Treatment selection for DPN requires careful consideration of patient goals, functional status, and potential adverse effects.
• A stepwise approach utilizing guideline-recommended medications is advised.
• Many complementary therapies lack robust evidence for DPN treatment.